2025年ASCO前期报告

May 2025 Summary Abstracts from the 2025Annual Meeting of the American Society of Clinical Oncology (ASCO) were released May22ndat 5pm EDT. The 2025ASCO meeting will be held in Chicago fromMay 30th–June3rd, 2025. We have highlighted some key abstracts with analyses. Included at the end of the report is a list of the ASCO dataevents we have added from the Thursday release and Friday morning announcements. While this is just a briefoverview, we will be available todiscuss any data of interest in further detail. Please emailBiomedtrackeror call yoursales representative. Additionally, keep an eye out for our ASCO weekend updates and live-coverage when themeeting takes place. As a reminder, our ASCO coverage will continue throughout the conference and beyond. Our coverage will include: •June1-ASCO Weekend Update•Shortly following the conference-Post-ASCO Report andPodcast•June 11–Post-ASCO Webinar About the Author Biomedtrackeris an independent research service that offers proprietary clinical assessments and patient-basedrevenue forecasts of developmental drugs within a comprehensive and intuitive drug information database. Clientsfrom the pharmaceutical, biotech, and investment industries rely on Biomedtracker for its insight on the likelihood ofapproval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape ofevery important disease and indication. Over thelast several years, Biomedtracker has become the leader inproviding objective information alongside evidence based clinical assessments and investment research on pipelinedrugs worldwide. For more information on getting direct access to Biomedtracker, please emailclientservices@evaluate.com. Disclaimer Copyright © 2025Evaluate, a Norstella company This report is published byEvaluate(the Publisher). This report contains information from reputable sources andalthough reasonable efforts have been made to publish accurate information, you assume soleresponsibility for theselection, suitability and use of this report and acknowledge that the Publisher makes no warranties (eitherexpress orimplied) as to, nor accepts liability for, the accuracy or fitness for a particular purpose of the information or advicecontained herein. The Publisher wishes tomake it clear that any views oropinions expressed in this report byindividualauthors or contributors are their personal views and opinions and do not necessarily reflect theviews/opinions of the Publisher. Table of Contents ZIFTOMENIB FOR ACUTE MYELOGENOUS LEUKEMIA (AML).....................................................3INQOVI FOR ACUTE MYELOGENOUS LEUKEMIA (AML) .............................................................6SASANLIMAB FOR BLADDER CANCER.........................................................................................9BAVENCIO FOR BLADDER CANCER ...........................................................................................12INB-200 FOR BRAIN CANCER (MALIGNANT GLIOMA; AA AND GLIOBLASTOMA (GBM)).........15VECTIBIX FOR COLORECTAL CANCER (CRC)..............................................................................17OLOMORASIB FOR COLORECTAL CANCER (CRC)......................................................................20OPDIVO FOR ESOPHAGEAL CANCER ........................................................................................23OPDIVO FOR GASTRIC CANCER ................................................................................................26SATRI-CEL FOR GASTRIC CANCER .............................................................................................29PETOSEMTAMAB FOR HEAD AND NECK CANCER ....................................................................33BCA101 FOR HEAD AND NECK CANCER ...................................................................................36ITOVEBI FOR HR+/HER2- BREAST CANCER ...............................................................................39DALPICICLIB FOR HR+/HER2- BREAST CANCER ........................................................................42OBX-115 FOR MELANOMA .......................................................................................................45LYNOZYFIC FOR MULTIPLE MYELOMA (MM) ...........................................................................47TAGRISSO FOR NON-SMALL CELL LUNG CANCER (NSCLC) .......................................................50ZIPALERTINIB FOR NON-SMALL CELL LUNG CANCER (NSCLC) .................................................53IMNN-001 FOR OVARIAN CANCER ...........................................................................................57CAN-2409 FOR PROSTATE CANCER ..........................................................................................60CASDATIFAN FOR RENAL CELL CANCER (RCC)..........................................................................63ZEPZELCA FOR SMALL CELL LUNG CANCER (SCLC) ...........................................................